Literature DB >> 17894015

A novel overlap syndrome: systemic sclerosis associated with antiphospholipid syndrome--a case series.

Gisele Zandman-Goddard1, Nurit Tweezer-Zaks, Tamar Shalev, Yair Levy, Michael Ehrenfeld, Pnina Langevitz.   

Abstract

Antiphospholipid syndrome (APS) can be either primary or secondary to autoimmune diseases, malignancies, infectious diseases, or drug-induced conditions. The aim of this study was to describe a novel overlap syndrome of APS and systemic sclerosis (SSc) in a case series. A retrospective review of medical files of hospitalized patients who were followed in two rheumatology clinics in Israel for the diagnosis of SSc and APS was sought. A MEDLINE search was performed for reports of APS/SSc overlap syndrome. Five patients with the overlap syndrome of APS and SSc were retrieved. The diagnosis of both diseases was confirmed by the American College of Rheumatology classification criteria. Four patients were women and of an older age group (42-68 years old). Three patients had primary APS, and in two patients APS was secondary to SSc. Two of the five patients died. The interval between APS and SSc was < 1-18 years. APS/SSc overlap syndrome is described for the first time as a case series. The patients may be older, with an interval of up to 18 years between diseases. The APS patients did not suffer from SLE. The overlap syndrome was characterized in certain instances with severe disease and two patients died. With relevant clinical manifestations, APS should be sought in SSc patients and treated appropriately.

Entities:  

Mesh:

Year:  2007        PMID: 17894015     DOI: 10.1196/annals.1422.053

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  11 in total

1.  Systemic sclerosis sine scleroderma associated with antiphospholipid syndrome.

Authors:  Pollyanna d'Ávila Leite; Jozélio Freire de Carvalho
Journal:  Rheumatol Int       Date:  2010-04-09       Impact factor: 2.631

2.  Antiphospholipid antibodies in systemic sclerosis: a double oxidative hit?

Authors:  Paul R J Ames
Journal:  Clin Rheumatol       Date:  2009-06-10       Impact factor: 2.980

3.  Intravenous immunoglobulins for rheumatic disorders and thromboembolic events-a case series and review of the literature.

Authors:  Merav Lidar; Sewar Masarwa; Pnina Rotman; Or Carmi; Noa Rabinowicz; Yair Levy
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

Review 4.  Coagulation and autoimmunity in scleroderma interstitial lung disease.

Authors:  Anna Ludwicka-Bradley; Richard M Silver; Galina S Bogatkevich
Journal:  Semin Arthritis Rheum       Date:  2010-12-17       Impact factor: 5.532

5.  Lower extremity ulcers in systemic sclerosis: features and response to therapy.

Authors:  Victoria K Shanmugam; Patricia Price; Christopher E Attinger; Virginia D Steen
Journal:  Int J Rheumatol       Date:  2010-08-18

Review 6.  Vascular disease in scleroderma.

Authors:  Fredrick M Wigley
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

7.  Coexistence of five autoimmune diseases: diagnostic and therapeutic difficulties.

Authors:  Ewa Wielosz; Maria Majdan; Iwona Zychowska; Radosław Jeleniewicz
Journal:  Rheumatol Int       Date:  2008-03-05       Impact factor: 2.631

8.  Treatment resistant severe digital ischemia associated with antiphospholipid syndrome in a male patient with systemic sclerosis.

Authors:  Orhan Küçükşahin; Aşkın Ateş; Alexis K Okoh; Emre Kulahcioglu; Murat Turgay; Gülay Kınıklı
Journal:  Case Rep Rheumatol       Date:  2014-07-08

9.  Scleroderma renal crisis in tropical region: two senegalese cases.

Authors:  Mouhamadou Moustapha Cisse; Sidy Mohamed Seck; Daher Abdoul Karim Oumar; Khodia Fall; Ahmed Tall Lemrabott; Moussa Diallo; Maria Faye; Moustapha Faye; Abdou Niang; Boucar Diouf
Journal:  Pan Afr Med J       Date:  2015-05-22

10.  Influence of antiphospholipid antibody positivity on glomerular filtration rate markers in a group of systemic sclerosis patients - a 24-month observation.

Authors:  Ewa Wielosz; Maria Majdan; Arkadiusz Koszarny; Magdalena Dryglewska; Jacek Tabarkiewicz
Journal:  Cent Eur J Immunol       Date:  2017-08-08       Impact factor: 2.085

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.